Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Presenilin enhancer 2 (PEN-2)–ATP6AP1–vacuolar-type H+-ATPase (v-ATPase) complex is a multi-protein assembly on the lysosomal membrane that serves as a critical junction between cellular energy status and metabolic signaling (Lin et al., 2022, Nature). PEN-2, traditionally recognized as an essential subunit of the gamma-secretase complex involved in the proteolytic processing of the amyloid precursor protein (APP) (UniProt Q9NZ42), has been recently identified to function as a direct sensor for cytosolic glucose. When glucose levels are low, PEN-2 binds to the ATP6AP1 (Ac45) subunit of the v-ATPase, facilitating the recruitment of the AXIN-LKB1 complex to the lysosome to activate AMP-activated protein kinase (AMPK) (PubMed 35322231). This interaction effectively couples the cell's nutrient-sensing machinery with the v-ATPase proton pump, which is responsible for maintaining the acidic environment necessary for lysosomal degradation. Because of its dual role in both metabolic regulation and neurodegeneration-linked proteolysis, this complex is a high-interest therapeutic target for conditions such as type 2 diabetes, obesity, and Alzheimer's disease. However, pharmacological modulation of this complex poses significant challenges, as disrupting PEN-2's function could interfere with Notch signaling or lead to lysosomal dysfunction (Lin et al., 2022, Nature).
Facilitates lysosomal AMPK activation in response to low glucose levels by bridging the v-ATPase complex and AMPK (Lin et al., 2022, Nature).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Presenilin enhancer 2–ATP6AP1–vacuolar-type H+-ATPase complex (PEN2–ATP6AP1–v-ATPase).